On a quest to expand the eligible patient pool for its fast-growing liver disease drug Rezdiffra, Madrigal Pharmaceuticals ...

CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced two-year results from the open-label arm of ...

Madrigal Pharmaceuticals has a first mover advantage in the huge MASH market due to the approval of Rezdiffra. Read whether I ...

Short interest in Madrigal Pharmaceuticals rose to a four-month high, Ortex data showed, as bearish positions increased ...

Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease ...

We recently published a list of Billionaire John Paulson’s 10 Stocks with Huge Upside Potential. In this article, we are ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

The company’s flagship product, Rezdiffra, has shown strong commercial performance since its FDA approval in March 2024, becoming the first approved therapy for F2-F3 MASH in the U.S. In the ...

A large trial showed that the weight-loss drug could reduce liver inflammation and scarring caused by a common condition.

In a new study, Ozempic - a drug sold to help with obesity and diabetes - is attributed to helping this disease.

CEO Bill Sibold highlighted the momentum of Rezdiffra’s US launch, reporting $137 million in net sales for Q1 2025, reflecting a 33% increase quarter-over-quarter despite typical Q1 industry ...

Rezdiffra™ (resmetirom) net sales of $137.3 million As of March 31, 2025, more than 17,000 patients on Rezdiffra Two-year compensated MASH cirrhosis (F4c) data from MAESTRO-NAFLD-1 trial selected as ...